OBJECTIVES To assess safety and efficacy of 90Y resin microspheres administration using undiluted non-ionic contrast material (UDCM) {100% Omnipaque-300 (Iohexol)} in both the "B" and "D" lines. MATERIALS AND METHODS We reviewed all colorectal cancer liver metastases patients treated with 90Y resin microspheres radioembolization (RAE) from 2009 to 2017. As of April 2013, two experienced operators started using UDCM (study group) instead of standard sandwich infusion (control group). Occurrence of myelosuppression (leukopenia, neutropenia, erythrocytopenia or/and thrombocytopenia), stasis, nontarget delivery (NTD), median fluoroscopy radiation dose (FRD), median infusion time (IT), liver progression-free (LPFS) and overall survivals (OS) was evaluated. Complications within 6 months post-RAE were reported according to CTCAE v3.0 criteria. RESULTS Study and control groups comprised 23(28%) and 58(72%) patients, respectively. Median follow-up was 9.1 months. There was no statistically significant difference in myelosuppression incidence within 6 months post-RAE between groups. Median FRD and IT for study and control groups were 44.6 vs. 97.35 Gy/cm2 (p = 0.048) and 31 vs. 39 min (p = 0.006), respectively. A 38% lower stasis incidence in study group was not significant (p = 0.34). NTD occurred in 1/27(4%) study vs. 5/73(7%) control group procedures (p = 1). Grade 1-2 and grade 3-4 toxicities between study and control group patients were 36%(8/22) vs. 45%(26/58), p = 0.61 and 9%(2/22) vs. 16%(9/58), p = 0.72, respectively. There was no difference in LPFS and OS between groups. CONCLUSION Administration of 90Y resin microspheres using UDCM in both lines is safe and effective, resulting in lower fluoroscopy radiation dose and shorter infusion time, without evidence of myelosuppression or increased stasis incidence.

中文翻译：

---

使用全强度对比材料的90Y树脂微球体放射栓塞治疗结肠癌肝转移。

目的在“ B”和“ D”行中评估使用未稀释的非离子对比剂（UDCM）{100％Omnipaque-300（Iohexol）}使用90Y树脂微球的安全性和有效性。材料与方法我们回顾了2009年至2017年所有接受90Y树脂微球放射栓塞（RAE）治疗的大肠癌肝转移患者。截至2013年4月，两名经验丰富的操作员开始使用UDCM（研究组）代替标准的三明治输注（对照组）。发生骨髓抑制（白细胞减少，中性粒细胞减少，红细胞减少或/和血小板减少），淤滞，非靶标递送（NTD），中位透视检查辐射剂量（FRD），中位输注时间（IT），无肝进展（LPFS）和总生存期（OS） ）进行了评估。根据CTCAE v3报告了RAE后6个月内的并发症。0条条件。结果研究和对照组分别包括23（28％）和58（72％）患者。中位随访时间为9.1个月。在RAE后6个月内，两组之间的骨髓抑制发生率无统计学差异。研究组和对照组的FRD中位数和IT分别为44.6和97.35 Gy / cm2（p = 0.048）和31和39 min（p = 0.006）。研究组的瘀血发生率降低38％并不显着（p = 0.34）。NTD发生在1/27（4％）的研究中，而对照组的5/73（7％）发生了（p = 1）。研究组和对照组患者的1-2级和3-4级毒性分别为36％（8/22）和45％（26/58），p = 0.61和9％（2/22）对16％（ 9/58），p = 0.72。两组之间的LPFS和OS没有差异。